Radiotheranostic pair 68Ga/177Lu-NYM096 targets metastatic kidney cancer

A new radiotheranostic pair, 68Ga/177Lu‑NYM096, has been shown to identify and treat metastatic clear cell renal cell carcinoma (ccRCC) with reduced toxicity. The compound, a small‑molecule agent, was evaluated in patients with end‑stage disease and demonstrated both effective tumor imaging and targeted radiotherapy in a single therapeutic cycle.

The study, published in the September issue of *The Journal of Nuclear Medicine*, highlights the dual diagnostic and therapeutic capabilities of the 68Ga/177Lu‑NYM096 pair. By combining a positron‑emitting isotope for imaging with a beta‑emitting isotope for therapy, clinicians can precisely locate ccRCC lesions and deliver localized radiation while minimizing systemic side effects. The small‑molecule design further improves safety by reducing off‑target accumulation compared with larger antibody‑based agents.

These findings suggest that 68Ga/177Lu‑NYM096 offers a safe and feasible strategy for patients with metastatic ccRCC, potentially improving outcomes for those with limited treatment options.